BBS-Bioactive Bone Substitutes (OSTO:BONES) ROCE % : -39.44% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BBS-Bioactive Bone Substitutes ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BBS-Bioactive Bone Substitutes's annualized ROCE % for the quarter that ended in Dec. 2023 was -39.44%.

BBS-Bioactive Bone Substitutes ROCE % Historical Data

The historical data trend for BBS-Bioactive Bone Substitutes's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BBS-Bioactive Bone Substitutes ROCE % Chart

BBS-Bioactive Bone Substitutes Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-16.63

-25.59

-24.73

-34.06

-37.27

BBS-Bioactive Bone Substitutes Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial											-27.98	-31.36	-31.18	-36.93	-39.44

BBS-Bioactive Bone Substitutes ROCE % Calculation

BBS-Bioactive Bone Substitutes's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-37.663	/	( ( (117.5 - 18.7)	+	(118.717 - 15.403) )	/ 2 )
	=	-37.663	/	( (98.8	+	103.314)	/ 2 )
	=	-37.663	/	101.057
	=	-37.27 %

BBS-Bioactive Bone Substitutes's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-40.114	/	( ( (125.157 - 25.038)	+	(118.717 - 15.403) )	/ 2 )
	=	-40.114	/	( ( 100.119	+	103.314 )	/ 2 )
	=	-40.114	/	101.7165
	=	-39.44 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

BBS-Bioactive Bone Substitutes (OSTO:BONES) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BBS-Bioactive Bone Substitutes ROCE % Related Terms

Thank you for viewing the detailed overview of BBS-Bioactive Bone Substitutes's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BBS-Bioactive Bone Substitutes (OSTO:BONES) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BBS-Bioactive Bone Substitutes PLC (OSTO:BONES) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BONEH:Finland

Address

Kiviharjunlenkki 6, Oulu, FIN, 90220

Website

http://www.bbs-artebone.fi

BBS-Bioactive Bone Substitutes PLC is a health technology company, that develops, designs, and manufactures bioactive bone-graft substitute implants. Its ortho-biological product ARTEBONE, which is based on tricalcium phosphate and a natural spectrum of bone proteins has the capability of bone regeneration.

BBS-Bioactive Bone Substitutes (OSTO:BONES) Headlines

No Headlines